Study Guide For Supportive Care - 842

Study Guide For Supportive Care – 842 Supportive Care CINV (24 questions) • • • • • • • • • • Know brand (when provided in the lecture) and generics for all of the drugs we discussed in CINV Know MOA of the different agents we discussed (5HT3 antagonists, etc) Safety profiles of the drugs we discussed – no IV Anzemet in cancer patients, Aloxi vs. Zofran differences in administration, dosing, and safety. Be able to determine risk of emetogenicity when given a percentage or tell me the percentage when given a high, moderate, low, or minimal regimen. Understand the pathophysiology of CINV – how does it happen, what brain structures are involved, what neurotransmitters are we targeting. Risk factors for the different CINV types and what kinds are there – (acute, delayed, anticipatory, refractory, breakthrough) Recall the classifications of the different types of cannabinoids – we talked about both major and minor and whether or not they were psychoactive (ie. THC, etc) Be able to recommend an appropriate antiemetic regimen based on a patient’s individual risk factors and based on the emetogenicity risk of their regimen. We discussed an advantageous drug interaction between a few of the NK-1 receptor antagonists and dexamethasone so please be familiar with that Recall some of the potential ADRs and toxicities of adjunctive/salvage/breakthrough treatments for CINV CIA (16 questions) • • • • • • • • • Know the causes of anemia in cancer patients; including the pathophysiology associated with anemia Be able to use a table to determine what grade of anemia a patient has We discussed how receiving a transfusion can influence certain parameters like Hgb and HCT – know the point increases Pros and cons of ESAs vs. Transfusions Definition of anemia per NCCN guidelines How do we approach a patient who refuses blood products? How do we decide when to start an ESA or blood transfusion in a patient – based on the guideline recommendations – symptomatic vs. asymptomatic (w/ or w/out risk factors) Dose adjust and evaluate ESAs for response or lack of response MOA and ADRs associated with ESAs and precautions with their use FN (16 questions) • • • • • • • • • • • Define FN Pathophysiology of FN, especially related to chemotherapy damaging bone marrow Nadir definition MOAs of GM and GCSFs as well as major ADRs Pegylated vs. non-pegylated forms of GCSFs from a dosing perspective – how often do we give? When and how do we use GM and GCSFs How do we determine the risk of febrile neutropenia in a regimen? High, moderate, low percentages What are some of the major causes of febrile neutropenia Where do we draw blood cultures from What is the pathophysiology of bone pain in GCSFs and how do we manage it How do we decide whether or not we treat a patient inpatient or outpatient with FN SCD (4 questions) • What is SCD and who does it primarily impact? • What kinds of health disparities occur in patients affected by SCD? • Pathophysiology of SCD • Acute vs chronic pain • Hydroxyurea MOA and clinical pearls • Complications patients may experience